S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
66,000% upside on tiny biotech? (Ad)
AI powerhouse NVIDIA will hit $1000 soon
Roku stock and the mother of all entry opportunities
66,000% upside on tiny biotech? (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
66,000% upside on tiny biotech? (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
66,000% upside on tiny biotech? (Ad)
AI powerhouse NVIDIA will hit $1000 soon
Roku stock and the mother of all entry opportunities
66,000% upside on tiny biotech? (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
66,000% upside on tiny biotech? (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
66,000% upside on tiny biotech? (Ad)
AI powerhouse NVIDIA will hit $1000 soon
Roku stock and the mother of all entry opportunities
66,000% upside on tiny biotech? (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
66,000% upside on tiny biotech? (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
66,000% upside on tiny biotech? (Ad)
AI powerhouse NVIDIA will hit $1000 soon
Roku stock and the mother of all entry opportunities
66,000% upside on tiny biotech? (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
66,000% upside on tiny biotech? (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
NASDAQ:PHVS

Pharvaris (PHVS) Stock Price, News & Analysis

$27.78
-0.03 (-0.11%)
(As of 02/22/2024 ET)
Today's Range
$27.46
$28.85
50-Day Range
$25.00
$32.07
52-Week Range
$6.02
$33.00
Volume
82,426 shs
Average Volume
132,070 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$29.75

Pharvaris MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
7.1% Upside
$29.75 Price Target
Short Interest
Healthy
1.41% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.12mentions of Pharvaris in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.30) to ($2.15) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.31 out of 5 stars


PHVS stock logo

About Pharvaris Stock (NASDAQ:PHVS)

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.

PHVS Stock Price History

PHVS Stock News Headlines

We Could Be Less Than 3 Months Out from an AI Superevent
According to one of the world’s top AI scientists, there’s a major event coming as soon as three months from today that could cause expensive tech stocks like Microsoft, Google, and NVIDIA to double or triple in price in the months ahead… but whatever you do, don’t go all in on big tech before you have all the details.
Pharvaris Announces Extraordinary Meeting of Shareholders
Pharvaris Announces Extraordinary Meeting of Shareholders
Pharvaris (NASDAQ:PHVS) Rating Reiterated by JMP Securities
Wedbush Reaffirms Their Buy Rating on Pharvaris (PHVS)
Pharvaris to Present at the WSAAI Annual Meeting 2024
Porter Stansberry exposes $100 billion hoax
: Artificial Illusion They say it’s the “biggest advancement in modern history…” But THEY’RE WRONG. Artificial intelligence is an Artificial Illusion. Which means if you own AI stocks, you need to watch this film now before it’s too late.
Pharvaris: Digging Deep For Sufficient Market Size
See More Headlines
Receive PHVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pharvaris and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
2/22/2024
Next Earnings (Estimated)
4/03/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PHVS
Fax
N/A
Employees
70
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$29.75
High Stock Price Target
$49.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+7.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$-80,420,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.94 per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
-3.02
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. Berndt Axel Edvard Modig CPA (Age 65)
    M.B.A., Co-Founder, CEO & Executive Director
    Comp: $543.71k
  • Ms. Anna Nijdam M.Sc. (Age 43)
    R.A., Head of Strategic Finance & Principal Accounting Officer
  • Ms. Joan Schmidt J.D. (Age 60)
    Chief Legal Officer
  • Dr. Peng Lu M.D. (Age 46)
    Ph.D., Chief Medical Officer
  • Dr. Anne A. Lesage Ph.D. (Age 63)
    Chief Early Development Officer
  • Dr. Morgan Conn Ph.D. (Age 55)
    Chief Business Officer
  • Mr. Wim Souverijns Ph.D. (Age 53)
    Chief Community Engagement & Commercial Officer
  • Dr. Stefan Abele Ph.D. (Age 54)
    Chief Technology Operations Officer
  • Maryann Cimino
    Director of Corporate Relations
  • Ms. Annick Deschoolmeester (Age 51)
    Chief Human Resources Officer














PHVS Stock Analysis - Frequently Asked Questions

Should I buy or sell Pharvaris stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pharvaris in the last twelve months. There are currently 1 sell rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" PHVS shares.
View PHVS analyst ratings
or view top-rated stocks.

What is Pharvaris' stock price target for 2024?

4 brokerages have issued 12 month target prices for Pharvaris' shares. Their PHVS share price targets range from $11.00 to $49.00. On average, they anticipate the company's stock price to reach $29.75 in the next year. This suggests a possible upside of 7.1% from the stock's current price.
View analysts price targets for PHVS
or view top-rated stocks among Wall Street analysts.

How have PHVS shares performed in 2024?

Pharvaris' stock was trading at $28.05 at the beginning of 2024. Since then, PHVS shares have decreased by 1.0% and is now trading at $27.78.
View the best growth stocks for 2024 here
.

Are investors shorting Pharvaris?

Pharvaris saw a increase in short interest in January. As of January 31st, there was short interest totaling 212,300 shares, an increase of 272.5% from the January 15th total of 57,000 shares. Based on an average trading volume of 161,700 shares, the days-to-cover ratio is presently 1.3 days. Approximately 1.4% of the shares of the stock are short sold.
View Pharvaris' Short Interest
.

When is Pharvaris' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 3rd 2024.
View our PHVS earnings forecast
.

How were Pharvaris' earnings last quarter?

Pharvaris (NASDAQ:PHVS) announced its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.39) earnings per share for the quarter, topping analysts' consensus estimates of ($0.49) by $0.10.

When did Pharvaris IPO?

(PHVS) raised $126 million in an initial public offering on Friday, February 5th 2021. The company issued 7,000,000 shares at $17.00-$19.00 per share. Morgan Stanley, BofA Securities and SVB Leerink served as the underwriters for the IPO and Oppenheimer & Co. and Kempen & Co. were co-managers.

Who are Pharvaris' major shareholders?

Pharvaris' stock is owned by a variety of retail and institutional investors. Top institutional investors include venBio Partners LLC (15.45%), Bain Capital Life Sciences Investors LLC (0.00%), Viking Global Investors LP (11.49%), Novo Holdings A S (4.83%), Price T Rowe Associates Inc. MD (2.65%) and Price T Rowe Associates Inc. MD (0.00%).

How do I buy shares of Pharvaris?

Shares of PHVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PHVS) was last updated on 2/23/2024 by MarketBeat.com Staff